Lar haplotype assays (BioTest ABC SSPtray; BioTest Diagnostics Corp, Denville, NJ). Vaccinia-specific CD8 T-cell IFN and MIP-1 production was by flow cytometry measured using stimulation with live vaccinia virus (NYCBH strain) at an MOI of 5 as described by Precopio et al [18]. ELISPOT assays were performed utilizing MabtechTM ELISpot plus Human Interferon-gamma kits (MABTECH AB, Sweden). Cryopres
Lar haplotype assays (BioTest ABC SSPtray; BioTest Diagnostics Corp, Denville, NJ). Vaccinia-specific CD8 T-cell IFN and MIP-1 production was by flow cytometry measured using stimulation with live vaccinia virus (NYCBH strain) at an MOI of 5 as described by Precopio et al [18]. ELISPOT assays were performed utilizing MabtechTM ELISpot plus Human Interferon-gamma kits (MABTECH AB, Sweden). Cryopres
Tudy exclusion criteria included chronic neurological disorder, head injury, uncontrolled seizure disorder, experimental drugs or vaccination within the past 15 days, radiation or chemotherapy within prior month, mental condition involving inability to understand, chronic alcohol or drug abuse, pregnancy, opportunistic infection, cancer, medical condition (heart, liver or kidney) or MR contraindic
S described in Table 2. Positive controls included SEB, PHA, and CEF. Negative controls included wells with mediumNIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptVaccine. Author manuscript; available in PMC 2010 March 26.Greenough et al.Pageand cells but no stimulus. This background was subtracted from results of wells with peptides in the analyses. Positive responses wer
S described in Table 2. Positive controls included SEB, PHA, and CEF. Negative controls included wells with mediumNIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptVaccine. Author manuscript; available in PMC 2010 March 26.Greenough et al.Pageand cells but no stimulus. This background was subtracted from results of wells with peptides in the analyses. Positive responses wer
S described in Table 2. Positive controls included SEB, PHA, and CEF. Negative controls included wells with mediumNIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptVaccine. Author manuscript; available in PMC 2010 March 26.Greenough et al.Pageand cells but no stimulus. This background was subtracted from results of wells with peptides in the analyses. Positive responses wer
Ents/the study: MCL MAM KKH TCG SA DCP GT GS JS DMM BFH. Analyzed the data: MAM KKH DJM JDA TCG SA BBH DCP MC GT PAG HXL BFH. Collected data/did experiments for the study: MCL MAM KKH DJM JFW JDA TCG SA BBH NAV SP DCP MC GT GS JE NJS CBH HXL MM GHK BFH. Enrolled patients: MC PAG GS JE CBH MM DMM. Wrote the first draft of the paper: MCL BFH. Contributed to the writing of the paper: MCL MAM BBH NAV
Ministered to HIV-infected young adults on highly active antiretroviral therapy (HAART).NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript2.2. Vaccine2. Materials and methodsThis was a prospective, multicenter trial carried out by the Pediatric AIDS Clinical Trials Group (PACTG) and the International Maternal, Pediatric, Adolescent, AIDS Clinical Trials (IMPAACT) network. T